ProfileGDS5678 / 1434683_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 81% 82% 82% 84% 86% 83% 86% 82% 81% 82% 82% 80% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3309785
GSM967853U87-EV human glioblastoma xenograft - Control 25.8238781
GSM967854U87-EV human glioblastoma xenograft - Control 35.9361782
GSM967855U87-EV human glioblastoma xenograft - Control 46.0804682
GSM967856U87-EV human glioblastoma xenograft - Control 56.2658784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2858586
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9431183
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4961686
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9579882
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7941281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9118582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9416882
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7048580
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9453982